Novavax vaccine recommended for approval for EU teenagers
A positive recommendation from the EU committee CHMP concerning the use of the Novavax vaccine in teenagers has turned Novavax’s stock fortunes upside down after months of losses.
by marketwire, translated by catherine brett
Shares in US-based vaccine producer Novovax increased in value by 13.9% on Thursday in US trading after the Committee for Medicinal Products for Human Use, the CHMP, recommended the vaccine be used in children aged 12-17.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Moderna on booster race: May the best data win
For subscribers
EMA begins review of Novavax's Covid-19 vaccine
For subscribers
Epidemiologist calls Pfizer's corona pill a "game changer"
For subscribers
.jpg&w=384&q=75)
